Polymorphisms in the human paraoxonase (PON1) promoter
- 1 February 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 11 (1), 77-84
- https://doi.org/10.1097/00008571-200102000-00009
Abstract
Paraoxonase (PON1) is a protein component of high-density lipoprotein (HDL) particles that protects against oxidative damage to both low-density lipoprotein and HDL and detoxifies organophosphorus pesticides and nerve agents. A wide range of expression levels of PON1 among individuals has been observed. We examined the promoter region of PON1 for genetic factors that might affect PON1 activity levels. We conducted a deletion analysis of the PON1 promoter region in transient transfection assays and found that cell-type specific promoter elements for liver and kidney are present in the first 200 bp upstream of the coding sequence. Sequence analysis of DNA from a BAC clone and a YAC clone identified five polymorphisms in the first 1000 bases upstream of the coding region at positions −108, −126, −162, −832 and −909. Additionally, the promoter sequences of two individuals expressing high levels of PON1 and two individuals expressing low levels of PON1 were analysed. The two polymorphisms at −126 and −832 had no apparent effect on expression level in the reporter gene assay. The polymorphisms at position −909, −162 (a potential NF-I transcription factor binding site) and −108 (a potential SP1 binding site) each have approximately a two-fold effect on expression level. The expression level effects of the three polymorphisms appear not to be strictly additive and may depend on context effects.Keywords
This publication has 45 references indexed in Scilit:
- Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotypePharmacogenetics, 2000
- CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressorsAIDS, 2000
- Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase responseAtherosclerosis, 1998
- Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.Journal of Clinical Investigation, 1998
- Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.Journal of Clinical Investigation, 1997
- The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarinNature Genetics, 1996
- Structural Organization of the HumanPON1GeneGenomics, 1996
- A pitfall of using a second plasmid to determine transfection efficiencyNucleic Acids Research, 1992
- Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesteraseAnalytical Biochemistry, 1989
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977